
|Articles|September 1, 2011
- Pharmaceutical Executive-09-01-2011
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - September 2011
From Many, One
Advertisement
Articles in this issue
over 14 years ago
Pharm Exec's 10th Annual Industry Auditover 14 years ago
Pharma and Social Media: Ready to Make Nice?over 14 years ago
The Power of Product Development Partnershipover 14 years ago
Front and Center in the Fight against TBover 14 years ago
How to Recruit 70,000 People in One Yearover 14 years ago
Innovating Around Innovationover 14 years ago
India: Good Endings, Good Beginnings!over 14 years ago
Two Million Man Hoursover 14 years ago
Rebates and Reformover 14 years ago
Should the US Gamble with Risk Sharing?Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
3
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
4
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
5




